LYSODREN Drug Patent Profile
✉ Email this page to a colleague
When do Lysodren patents expire, and what generic alternatives are available?
Lysodren is a drug marketed by Hra Pharma and is included in one NDA.
The generic ingredient in LYSODREN is mitotane. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the mitotane profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LYSODREN?
- What are the global sales for LYSODREN?
- What is Average Wholesale Price for LYSODREN?
Summary for LYSODREN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 104 |
| Clinical Trials: | 4 |
| Patent Applications: | 4,363 |
| Drug Prices: | Drug price information for LYSODREN |
| What excipients (inactive ingredients) are in LYSODREN? | LYSODREN excipients list |
| DailyMed Link: | LYSODREN at DailyMed |
Recent Clinical Trials for LYSODREN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| M.D. Anderson Cancer Center | Phase 3 |
| European Network for the Study of Adrenal Tumors (ENS@T) | Phase 3 |
| Amercian Australian Asian Adrenal Alliance (A5) | Phase 3 |
Pharmacology for LYSODREN
| Mechanism of Action | Cytochrome P450 3A4 Inducers |
US Patents and Regulatory Information for LYSODREN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hra Pharma | LYSODREN | mitotane | TABLET;ORAL | 016885-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for LYSODREN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| HRA Pharma Rare Diseases | Lysodren | mitotane | EMEA/H/C/000521 Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established. |
Authorised | no | no | no | 2004-04-28 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
